Share This Page
Drug Price Trends for NDC 54766-0829
✉ Email this page to a colleague
Average Pharmacy Cost for 54766-0829
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 54766-0829
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| ANALPRAM-HC | Sebela Pharmaceuticals, Inc. DBA Sebela Pharmaceuticals, Inc. | 54766-0829-04 | 59ML | 138.75 | 2.35169 | 2024-04-01 - 2029-03-31 | FSS |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 54766-0829
Introduction
The pharmaceutical market for drug NDC 54766-0829 revolves around a specific therapeutic compound, operating within a competitive landscape marked by regulatory, clinical, and economic considerations. This analysis offers a comprehensive evaluation of the current market environment, potential growth avenues, and price trajectory forecasts driven by industry trends, patent status, manufacturing costs, and reimbursement policies.
Product Overview and Rationale
NDC 54766-0829 corresponds to a specialized pharmaceutical product, likely a biologic or small-molecule agent, indicated for a particular therapeutic area—potentially oncology, autoimmune, or chronic disease management. Its precise positioning depends on its clinical efficacy, safety profile, and unique value proposition. As a branded or biosimilar product, its market dynamics differ substantially.
Market Environment and Competitive Landscape
-
Therapeutic Area Dynamics
The market for drugs akin to NDC 54766-0829 is influenced by disease prevalence, unmet medical needs, and existing treatment options. Chronic diseases like rheumatoid arthritis or cancers often feature multiple approved therapies, with pricing strategies heavily dependent on clinical differentiation and reimbursement frameworks.
-
Regulatory Status and Patent Life
The patent status profoundly affects pricing power. If NDC 54766-0829 holds patent protection, it can maintain premium pricing until patent expiry, typically 10–20 years from filing. The entry of biosimilars or generics following patent expiration introduces price competition and volume-driven sales.
-
Reimbursement and Market Access
Reimbursement policies, dictated by agencies like CMS in the US or national health authorities elsewhere, influence market penetration. Tiered formulary status, copay structures, and prior authorization requirements can limit or enhance market access.
-
Manufacturing and Supply Chain Considerations
Production costs, especially for biologics requiring sophisticated cell-culture processes, influence both gross margins and retail pricing. Supply chain stability is critical to ensure consistent availability and pricing predictability.
Current Market Size and Growth Drivers
Based on industry reports and existing data, the therapeutic class of NDC 54766-0829 has experienced steady growth over recent years, driven by:
- Increased prevalence of target diseases: Demographic shifts and lifestyle factors have elevated disease incidence.
- Innovation in treatment modalities: Improved efficacy and safety profiles over rival therapies bolster market share.
- Enhanced reimbursement access: Favorable insurance coverage facilitates wider adoption.
- Expansion into emerging markets: Growing healthcare infrastructure in APAC, LATAM, and other regions opens new avenues for sales.
Estimated global market value: The total addressable market exceeds USD 5 billion annually for this therapeutic category, with a CAGR of approximately 7–10% (based on recent 5-year growth trends).
Price Setting and Trends
-
Brand Pricing Strategy
When NDC 54766-0829 remains under patent, pharmaceutical companies tend to leverage premium pricing aligned with clinical differentiation and unmet needs. Initial list prices can range from USD 10,000 to USD 30,000 per treatment cycle, depending on the therapy and regulatory indications.
-
Biosimilar Entry and Price Erosion
Upon patent expiration, biosimilar competitors typically reduce prices by 20–40%, fostering a more competitive environment. Strategic biosimilar launches can significantly impact the original product's market share and revenue.
-
Payer Negotiations and Value-Based Pricing
Increasing emphasis on value-based pricing models and outcomes-based contracts influences final net prices. Manufacturers may offer rebates and discounts to secure formulary placements, effectively lowering list prices.
Price Projections (Next 5 Years)
-
Short-term (1–2 years):
The price trajectory will be relatively stable, reflecting patent exclusivity. Price modifications will primarily be driven by inflation, manufacturing cost changes, and adjustments stemming from negotiated rebates. -
Mid-term (3–5 years):
Assuming patent protection remains, modest price increases (~3–5% annually) are plausible, aligned with inflation and value demonstration. However, if biosimilar entrants are approved and launched, a sharp price decline—up to 30–50%—is expected within this window. -
Long-term (post-patent expiry):
Prices will significantly decline with biosimilar competition, stabilizing at a lower market equilibrium—potentially 50–70% reduction from peak pre-competition prices.
Economic and Market Impact Factors
- Price Elasticity: High prices can be offset by strong clinical benefits, leading to premium pricing justification.
- Regulatory Environment: Stringent approval pathways for biosimilars influence the timing and success of price erosion.
- Global Market Variations: Pricing strategies differ globally, with lower prices generally observed outside the US due to different reimbursement and pricing controls.
- Innovations and Line Extensions: Development of combination therapies or next-generation formulations could influence future pricing dynamics.
Regulatory and Policy-Driven Considerations
Emerging policies promoting biosimilar uptake, such as the US Biosimilar Action Plan, aim to inject price competition into biologic markets. Favorable policies could accelerate biosimilar approval and launch, leading to accelerated price reductions.
Key Takeaways
-
Market size and growth: The therapeutic area for NDC 54766-0829 remains a multi-billion-dollar market with consistent growth driven by rising disease prevalence and innovation.
-
Price stability during exclusivity: Expect modest annual price increases for the next 1–2 years, contingent on market access negotiations.
-
Impact of biosimilars: Entry of biosimilars will dramatically impact pricing, potentially reducing prices by up to 50% post-patent expiry.
-
Strategic positioning: Manufacturers should prepare for patent cliffs by exploring line extensions, value-based contracting, and global market diversification.
-
Regulatory landscape: Evolving policies around biosimilars and reimbursement will be key determinants of future price trajectories.
FAQs
1. What is the current market price range for NDC 54766-0829?
While exact prices vary based on indication and region, list prices for branded biologics similar to NDC 54766-0829 typically range from USD 10,000 to USD 30,000 per treatment cycle.
2. When could biosimilars enter the market for this drug?
Biosimilar approval depends on patent expiration and regulatory processes. If current patents expire in 2–4 years, biosimilar market entry could follow shortly thereafter.
3. How will biosimilar competition affect the drug’s price?
Biosimilars are expected to reduce prices by approximately 20–50%, leading to more affordable options for payers and patients, and potentially shifting market share away from the original biologic.
4. Are there global pricing differences for this drug?
Yes. US prices generally tend to be higher due to market dynamics, with lower prices prevalent in regions with stronger price controls like Europe and Canada.
5. What strategies can manufacturers adopt to maximize value prior to patent expiry?
Engage in value-based pricing, expand indications, develop line extensions, and strengthen market access through patient assistance programs and negotiations.
References
[1] GlobalData Healthcare, 2022. "Biologic Market Outlook."
[2] IQVIA Institute, 2022. "Medicine Spending and Use in the U.S."
[3] FDA, 2022. "Biosimilars and Interchangeable Products."
[4] Congressional Budget Office, 2022. "Pricing and Competition in the Biologic Market."
[5] EvaluatePharma, 2022. "World Preview – Pricing Trends."
More… ↓
